

SEQUENCE LISTING

<110> Arrowhead Pharmaceuticals, Inc.
Carlson, Jeffrey C
Blokhin, Andrei V

<120> Biologically Cleavable Tetrapeptide Linking Agents

<130> 30630-W01

<150> 62168244
<151> 2015-05-29

<150> 62235833
<151> 2015-10-01

<160> 19

<170> PatentIn version 3.5

<210> 1
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> tetrapeptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = Citrulline

<400> 1

Ala Xaa Ala Ala
1

<210> 2
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> tetrapeptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = citrulline

<400> 2

Ala Xaa Ala Pro
1

<210> 3
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> tetrapeptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = citrulline

<400> 3

Ala Xaa Phe Pro
1

<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Factor 7 siRNA sense strand

<220>
<221> modified_base
<222> (1)..(19)
<223> ribonucleotide

<400> 4
gcaaaggcgu gccaacucat

20

<210> 5
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> tetrapeptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = Citrulline

<400> 5

Xaa Ala Ala Ala
1

<210> 6
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Factor 7 siRNA antisense strand

<220>

<221> modified_base
<222> (2)..(19)
<223> ribonucleotide

<400> 6
tgaguuggca cgccuugct t

21

<210> 7
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> tetrapeptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = Citrulline

<400> 7

Phe Xaa Ala Ala
1

<210> 8
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> tetrapeptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = Citrulline

<400> 8

Phe Xaa Ala Pro
1

<210> 9
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> tetrapeptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = Citrulline

<220>
<221> MISC_FEATURE

<222> (4)..(4)
<223> Xaa = N-methyl alanine

<400> 9

Phe Xaa Phe Xaa
1

<210> 10
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> tetrapeptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = Citrulline

<400> 10

Phe Xaa Phe Ala
1

<210> 11
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> tetrapeptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = Citrulline

<400> 11

Phe Xaa Phe Leu
1

<210> 12
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> tetrapeptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = Citrulline

<400> 12

Phe Xaa Phe Pro

1

<210> 13

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> tetrapeptide

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa = Citrulline

<400> 13

Phe Xaa Val Pro

1

<210> 14

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> tetrapeptide

<400> 14

Phe Asp Phe Pro

1

<210> 15

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> tetrapeptide

<400> 15

Phe Lys Phe Leu

1

<210> 16

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> tetrapeptide

<400> 16

Phe Lys Phe Pro

1

<210> 17
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> tetrapeptide

<400> 17

Phe Asn Phe Pro
1

<210> 18
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> tetrapeptide

<400> 18

Gly Phe Leu Gly
1

<210> 19
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> tetrapeptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = Citrulline

<400> 19

Val Xaa Phe Pro
1